Journal
ACTA PSYCHIATRICA SCANDINAVICA
Volume 123, Issue 3, Pages 175-189Publisher
WILEY-BLACKWELL
DOI: 10.1111/j.1600-0447.2010.01645.x
Keywords
bipolar disorder; mania; depression; treatment efficacy; adverse effects
Categories
Funding
- Abbott Laboratories
- AstraZeneca Pharmaceuticals
- Astellas Pharmaceuticals
- Bristol-Myers Squibb Company
- Cephalon
- Dainippon Sumitomo Pharmaceuticals
- Eli Lilly and Company
- GlaxoSmithKline
- Janssen Pharmaceutica
- Jazz Pharmaceuticals
- Johnson Johnson
- Novartis Pharmaceuticals
- Noven Pharmaceuticals
- Organon International, Inc.
- Otsuka Pharmaceuticals
- Pfizer, Inc.
- Repligen Corporation
- Solvay Pharmaceuticals
- Valeant Pharmaceuticals
- Vanda Pharmaceuticals
- Wyeth Pharmaceuticals
- XenoPort, Inc.
- Azur Pharma Inc
- Barr Laboratories
- Bristol-Myers Squibb
- Forest Research Institute
- Janssen Pharmaceuticals
- Schering-Plough Corporation
Ask authors/readers for more resources
Objective: To compare bipolar treatment interventions, using number needed to treat (NNT) and number needed to harm (NNH). Method: Results of randomized controlled clinical trials were used to assess efficacy (NNT for response and relapse/recurrence prevention vs. placebo) and tolerability (e.g. NNH for weight gain and sedation vs. placebo). Results: United States Food and Drug Administration-approved bipolar disorder pharmacotherapies all have single-digit NNTs (i.e. > 10% advantage over placebo), but NNHs for adverse effects that vary widely. Some highly efficacious agents are as likely to yield adverse effects as therapeutic benefit, but may be interventions of choice in more acute severe illness. In contrast, some less efficacious agents with better tolerability may be interventions of choice in more chronic mild-moderate illness. Conclusion: Clinical trials can help inform clinical decision making by quantifying the likelihood of benefit vs. harm. Integrating such data with individual patient circumstances, values, and preferences can help optimize treatment choices.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available